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A long-standing question for zoonotic
diseases is how animal reservoirs such as
bats immunologically control infection by
pathogens that often kill spillover hosts
such as humans. Guito et al. present clear
evidence that Marburg virus-infected
Egyptian rousette bats avert pathology by
limiting induction of proinflammatory
genes linked to severe disease.ll
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https://doi.org/10.1016/j.cub.2020.10.015SUMMARYMarburg virus (MARV) is among the most virulent pathogens of primates, including humans. Contributors to
severeMARV disease include immune response suppression and inflammatory gene dysregulation (‘‘cytokine
storm’’), leading to systemic damage and often death. Conversely, MARV causes little to no clinical disease in
its reservoir host, the Egyptian rousette bat (ERB). Previous genomic and in vitro data suggest that a tolerant
ERB immune response may underlie MARV avirulence, but no significant examination of this response in vivo
yet exists. Here, using colony-bred ERBs inoculated with a bat isolate of MARV, we use species-specific an-
tibodies and an immune gene probe array (NanoString) to temporally characterize the transcriptional host
response at sites of MARV replication relevant to primate pathogenesis and immunity, including CD14+mono-
cytes/macrophages, critical immune response mediators, primary MARV targets, and skin at the inoculation
site, where highest viral loads and initial engagement of antiviral defenses are expected. Our analysis shows
that ERBs upregulate canonical antiviral genes typical of mammalian systems, such as ISG15, IFIT1, and
OAS3, yet demonstrate a remarkable lack of significant induction of proinflammatory genes classically impli-
cated in primate filoviral pathogenesis, including CCL8, FAS, and IL6. Together, these findings offer the first
in vivo functional evidence for disease tolerance as an immunological mechanism by which the bat reservoir
asymptomatically hosts MARV. More broadly, these data highlight factors determining disparate outcomes
between reservoir and spillover hosts and defensive strategies likely utilized by bat hosts of other emerging
pathogens, knowledge that may guide development of effective antiviral therapies.INTRODUCTION
Egyptian rousette bats (ERBs, Rousettus aegyptiacus), cave-
dwelling fruit bats common across sub-Saharan Africa and parts
of the Middle East, have been identified as the Marburg virus
(MARV) natural reservoir.1,2 MARV, a member of the family Filo-
viridae that includes Ebola virus (EBOV), is the only human-path-
ogenic filovirus for which a natural reservoir has been identified.1
Filoviruses often cause fatal illness in spillover hosts such as hu-
mans and non-human primates (NHPs), yet distinctive of a reser-
voir species, MARV-infected ERBs remain asymptomatic.3–6
Experimentally infected ERBs develop low-level viremia that
peaks between days 5–7 post-infection, and typically shed infec-
tious virus in oral secretions for up to 3 weeks.3,5,6 Virus dissem-
inates widely, with highest levels found in liver and spleen, beforeCurrent Bio
This is an open access article under the CC BY-Nclearance within14 days.3,5,6 In contrast, MARV loads in blood
of infected NHPs are comparatively high, with death usually
occurring within 6–9 days.4,7,8 Much remains unknown about
how ERBs, along with bat reservoir species harboring other
zoonotic pathogens such as Nipah, Hendra, and SARS-related
coronaviruses, are able to control viral replication and mitigate
the severe disease these agents cause in primates.9–11 Eluci-
dating the immunological mechanisms likely facilitating this con-
trol in these bats, including cell, pathway, and molecular factors
contributing to disease protection, which in turn could inform
spillover dynamics and antiviral drug design, has increasingly
earned recognition as a core component of global initiatives to
prevent and prepare for emerging zoonotic disease outbreaks.
To date, at least two prominent immunoprotective mecha-
nisms in bat reservoirs have been posited. One mechanism,logy 31, 257–270, January 25, 2021 Published by Elsevier Inc. 257
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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viral replication through noncanonical means, such as quickly
mounting innate and adaptive immune responses from a pre-ex-
isting high basal state.12–14 This strategy has been postulated for
large Pteropus bats that carry Nipah and Hendra viruses.12,13
Another mechanism, disease tolerance, contends that bat hosts
have co-evolved with their respective resident pathogens to
tolerate infection, allowing viral replication only to levels suffi-
cient enough for transmission while concurrently mounting a
subdued antiviral immune response that controls clinical disease
(and tissue damage) by actively minimizing proinflammatory re-
sponses.11,14–17 This concept of tolerance is supported for
ERBs, as recent efforts to map the bat’s genome and transcrip-
tome has shown that this MARV reservoir (1) has diversified im-
mune-inhibitory domain-containing natural killer (NK) receptor
loci and accompanying expansion of major histocompatibility
(MHC) loci; (2) has expanded type I interferon (IFN) gene loci,
particularly of the IFNu family, that are less potently induced
in vitro, suggesting more subdued effector signaling; and (3) fails
to induce IFN genes even after ERB cell infection with a mutant
MARV that is incapable of antagonizing IFN-stimulated gene
(ISG) signaling.18–20 Further, infecting ERB bonemarrow-derived
dendritic cells (BMDCs) failed to increase inflammatory gene
expression, while experimental MARV infections of ERBs pro-
duced minimal, if any, gross histological signs of inflammation,
even in tissues with highest viral loads.3,5,6,21,22 The culmination
of these data led us to hypothesize that ERBs have indeed devel-
oped a system of disease tolerance to MARV. However, signifi-
cant testing of this hypothesis has so far been limited to immor-
talized cell lines, ex vivo tissue culture infections, or genomic
approaches that cannot reproduce or examine the complexity
and context of an immune response in a whole animal, which
to our knowledge remains uncharacterized at a broad transcrip-
tional level for any bat reservoir of a human-pathogenic virus,
including ERBs infected with MARV. A particularly important
focus of any in vivo host response study in MARV-infected
ERBs would be the role of monocytes and macrophages, as
these CD14+ immune cells, along with dendritic cells (DCs), are
primary sites of MARV infection in primates and are critical for
initiating innate and adaptive responses.4,7,23–25
To address these critical knowledge gaps,weconduct a 40-an-
imal in vivo time course experiment in which ERBs are inoculated
with a bat isolate of MARV (or sham control) and euthanized in
groups of five on days (D)1, 2, 3, 5, 8, 14, and 28 (or D13 for unin-
fected control bats).26 All bats come from our captive breeding
colony originally founded from ERBs caught in Uganda where
ERB-linked MARV outbreaks had occurred. Focusing on early
and acute phases of infection, we measure the ERB transcrip-
tional immune response at various tissue sites that are both
supportive of MARV replication in ERBs and important in primate
filoviral pathogenesis/immunity. These sites include skin at the
inoculationsite (where viral loadsarehighest and frontlinehostde-
fenses are likely) and spleen-derived CD14+ monocytes/macro-
phages, as well as whole spleen, liver, and colon.3,6,7,22,24,25 Our
study incorporated custom ERB-specific reagents, including an
anti-CD14 antibody used in tandem with positive magnetic bead
selection (MACS) of CD14+ splenocytes and a panel of 380 im-
mune-related gene probes (nCounter ERB CodeSet) used to
quantify differential gene expression (DGE) of total RNA extracted258 Current Biology 31, 257–270, January 25, 2021from tissues/CD14+ splenocytes. In this report, we demonstrate
in vivo that disease tolerance is a major strategy by which the
ERB reservoir host controls MARV infection, as opposed to a
model of initial resistance conferred by more potent antiviral de-
fenses.14 Specifically, we show significant induction of a cluster
of canonical antiviral genes (including DDX58 [RIG-I], IFIT1,
IRF7, ISG15, and OAS3) typical of viral infection in mammals,
but strikingly, almost no significant changes in expressionof tradi-
tionalmarkers of adaptive immunity or inflammation, including the
cytokines and chemokines IFNg, CCL8, FAS, and IL6, normally
associated with MARV pathogenesis in primates.8,25,27–31 Our
findings identify putative virulence-determining differences be-
tween reservoir and spillover host, as well as immunoprotective
commonalities likely shared between ERBs and bat reservoir
hosts of other emerging zoonotic pathogens (e.g., SARS, Ebola),
which could be exploitable for human therapeutic development.
RESULTS
CD14+ Splenocytes from MARV-Infected ERBs Are
Efficiently and Specifically MACS-Selected and Capable
of Robust Direct Infection
To validate that our ERB-specific anti-CD14 antibody could be
used within our time course MARV infection study to isolate
CD14+ monocytes/macrophages from ERB spleen with high
specificity and efficacy (along with separately using an anti-
CD19 antibody to target B lymphocytes), we quantified repre-
sentative monocyte and lymphocyte populations pre- and
post-MACS selection by flow cytometry using total splenocyte
suspensions harvested from MARV-infected ERBs during the
acute phase of infection at D5. Approximately 12% of spleno-
cytes were CD14+, while 44% stained CD19+ (Figures 1A and
1B). These percentages were moderately higher than ranges
previously identified for splenic monocytes/macrophages and
B cells of other mammals, including NHPs and P. alecto.32–35
This could be due to infiltration of activated macrophages into
the tissue (as the ERB spleens used for cytometry were collected
at the peak of viral infection whereas the prior mammalian data
were obtained from naive animals), naturally higher basal pro-
portions of resident CD14+ splenocytes in ERBs, or some degree
of both. Rat immunoglobulin G (IgG) isotype control showedmin-
imal events due to nonspecific protein binding (Figure 1C). These
stains were exclusive and based on gating of live, singlet cells
(Figure 1C). CD19+ cells had a forward-/side-scatter (FSC/
SSC) profile indicative of lymphocytes (Figure 1D, red), while
CD14+ cells were larger and had a profile indicative of mono-
cytes/macrophages (Figure 1D, blue). Following MACS, CD14+
and CD19+ splenocytes retained both their fluorescence proper-
ties (Figures 1E and 1F), with 95% CD14+ enrichment and
97%CD19+ enrichment compared to pre-cell isolation staining
or isotype control. Separately, ex vivo microscopy of MACS-
selected splenocytes from naive colony ERBs also showed mor-
phologies consistent with monocytes/macrophages (CD14+) or
lymphocytes (CD19+), and both populations were homoge-
neous, in contrast to the heterogeneity of total splenocytes (Fig-
ure S1A). To further validate that in vivo CD14+ splenocyte re-
sponses to MARV reflected direct infection of and replication in
monocytes/macrophages, which are primary MARV targets in
primates, we infected ex vivo CD14+ splenocytes from naive
Figure 1. ERB-Specific CD14 and CD19 An-
tibodies Detect and Magnetically Select
CD14+ or CD19+ Splenocyte Populations
with High Efficiency
(A and B) Proportions of live, singlet events for
CD14+ (A) (consistent with monocytes/macro-
phages) or CD19+ (B) (consistent with B lympho-
cytes), respectively, as measured by representative
PE fluorescence in total splenocyte suspensions
harvested from MARV-infected ERBs at D5.
(C) Gating strategy for flow cytometry on singlet,
live splenocyte sample events using rat IgG as a
negative isotype control stain to differentiate
nonspecific antibody binding.
(D) Overlapping forward- and side-scatter (FSC/
SSC) profiles of CD14+ (blue)/CD19+ (red) events
as determined in (A and B).
(E and F) Histogram profiles showing post-mag-
netic bead selection (MACS) enrichment of CD14+
or CD19+ populations visualized by PE fluores-
cence (orange), as compared to pre-selected
events (determined in A and B, shown in gray) and
IgG control events (blue).
See also Figure S1.
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isolate used for our ERB inoculations.7,21,25,26,36,37 This rMARV
encodes a ZsGreen (ZsG) fluorescent protein able to visualize
successful filovirus replication.36,37 As expected, CD14+ popula-
tions showed robust ex vivo infection, with ZsG fluorescence
increasing across the cell monolayer in both breadth and inten-
sity out to D3 (Figure S1B). Thus, these two species-specific an-
tibodies efficiently and selectively target andmagnetically isolate
ERB cells characteristic of monocytes/macrophages and B
cells, agreeing with their cytometric analysis in our previously
published BMDC ex vivo study, and ERB CD14+ monocytic cells
are a direct cellular target of MARV infection, reflecting the es-
tablished MARV tropism of their primate counterparts.7,21,25
MARV-Infected ERBs Become Temporarily Viremic with
Virus Dissemination to Tissues
MARV RNA levels in blood were first detected on D1, peaked at
D5, and were undetectable by D14 (Figure 2A). Consistent with
previous studies, similar viral RNA (vRNA) kinetics were observed
in skin at the inoculation site (Figure 2B) and in whole liver and
spleen (Figure 2C), persisting in the spleen for longer (D14) than
in liver or skin (D8).3,6,22 Bat #861 (D5cohort) had the highest over-
all vRNA levels detected for any animal and among the highest
blood vRNA levels at D4–D5 along with bats #319 (D8), #371
(D28), and #857 (D28), as well as #206 (D14) at D10 (Figures 2A
and 2C; Data S1). Characteristic of a negative-sense RNA virus,
viral gene counts in skin, as measured by nCounter (Figure 2B,
left), showed a mild 3ʹ to 5ʹ transcriptional gradient, while three
genomic vRNA targets measuring replication (vRNA 1–3) did not
(Figure 2B, right).37 This gradient is also observable in isolated
CD14+ splenocytes of bat #861 (Figure 2D, left, compared to
vRNA targets, right), further indicative of transcription/replication
in monocytic cells as previously observed in primate CD14+ pop-
ulations.24,25,37 Consistent with data from prior studies of ERBs
naturally or experimentally infected with MARV (including histol-
ogy), and in contrast to reports on severely ill MARV-infectedNHPs, we observed that all infected bats were asymptomatic
and tissues were without gross signs of inflammation.3,7,22
Early/Acute Phase Host Gene Responses in MARV-
Infected ERB Tissues Indicate Declining Lymphocyte
and Increasing Macrophage Proportions
Using total RNA probedwith the ERB CodeSet, we analyzed ERB
immune response gene expression focusing on CD14+ spleno-
cytes and skin (inoculation site). This targeted transcriptomics
data allowed us to utilize the CIBERSORT gene expression
profiling software to estimate proportionate trends in immune
cell populations in skin (Figures 3A and S2A) and spleen (Figures
3B and S2B) over the course ofMARV infection. Both tissues con-
sisted of DC, monocyte, macrophage, NK cell, and T and B
lymphocyte populations. As expected for mammals, higher esti-
mated proportions of monocytes/macrophages were seen in
skin and higher DC and lymphocyte proportions in spleen. NK
cells were a small, mostly stable population in both tissues, rising
transiently at D5 in spleen during peak viremia but significantly
decreasing by D5 and D8 in skin. In skin, mast cells and neutro-
phils proportionately increased (D1–D5) and decreased (D1–
D14) compared to control bats, respectively, with significant pro-
portional neutrophil decline on D8. Consistent with primate
studies, B cells showed marked proportional declines by D1
(skin, significantly so from D2–D14) and D5 (spleen) before
partially or fully recovering (or even significantly increasing
compared to uninfected bats as with splenic B cells from D8–
D28).4,7 T cell proportions modestly declined in skin (to a signifi-
cant degree on D8) without fully recovering by D28. Conversely,
macrophage proportions increased (D2–D5) in skin and spleen,
the latter of which show significant increases on D2 and D5, coin-
cidently with a proportional reduction of monocytes between
those time points. However, monocyte proportions in skin overall
showed expansion across the time course (significantly on D8
and D14) compared to uninfected bats; based on population
trends for individual bats (Figure S2A), this expansion appearsCurrent Biology 31, 257–270, January 25, 2021 259
Figure 2. Viral RNA Is Detected in Blood, Skin, and Whole Tissues from MARV-Infected ERBs with Kinetics like Previous Studies and Indi-
cates Viral Gene Transcription and Replication in CD14+ Splenocytes
(A) Daily viral RNA levels of all remaining individual bats were quantitated by MARV TaqMan assay of total RNA extracted from whole blood. Each time point
cohort was color-coded as indicated in figure legend at top, with each bat denoted by a different symbol. Pre, pre-inoculation.
(B) RNA level in skin for each nCounter-based MARV gene (left side) or each of three vRNA targets (right side) following nSolver analysis was calculated using the
average normalized counts for each infected or control bat cohort. Error bars indicate standard deviation of the averaged counts. Dotted red lines indicate
background count threshold value.
(C) Viral RNA levels for each individual bat were quantitated by MARV TaqMan assay of total RNA extracted from liver and spleen.
(D) CD14+ splenocyte nCounter-based normalized viral gene counts (left) or vRNA counts (right) were calculated for bat #861, the only bat in the CD14+ dataset
with MARV targets above background.
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high monocyte percentage identified for bat #557 among unin-
fected cohort members. Finally, bat #861 (D5), which had the
highest splenic viral load, showed the greatest reduction in B
cell percentage and greatest increase of NK/macrophage propor-
tions of all bats for that tissue type (Figure S2B).
MARV-Infected ERBs Show Broad Gene Induction in
CD14+ Splenocytes and Skin but an Overall Moderate,
Transient Immune Response that Includes Genes from
Functionally Related Classes
We measured fold-change (FC) of significantly differentially ex-
pressed genes (DEGs) in RNA from CD14+ splenocytes, skin,260 Current Biology 31, 257–270, January 25, 2021and whole tissues (spleen, liver, and colon/rectum) of MARV-in-
fected ERBs using the nCounter Advanced Analysis (nCAA) soft-
ware module. Both CD14+ splenocytes and skin showed early
gene induction (D1) and had highest DEG numbers (Figure S2C).
Skin and CD14+ splenocytes had 36 and 63 unique DEGs,
respectively, and shared an additional 42 targets (Figure S2D;
Table S1). Many of these unique and shared DEGs were from
functionally related gene classes. Complement and apoptosis
factors, IFN type I/II-related genes, and lymphocyte/DC/macro-
phage markers and regulatory genes were notable DEG classes
unique to skin (Table S1). CD14+ splenocyte-specific DEGs
included viral restriction, cell growth/stress response, and anti-
inflammatory factors, as well as TNF and kinase family members
Figure 3. Skin and Spleen Gene Expression Patterns Suggest
Lymphocyte Depletion and Monocyte Expansion following MARV
Infection of ERBs
Normalized nCounter gene counts from tissue datasets were analyzed by the
web-based CIBERSORT program to match time point-averaged ERB gene
expression from (A) skin or (B) spleen, to known signatures identified for human
marker genes of various immune cell types. Immune cell types identified in each
tissue are represented by color, and bar length of each indicates the relative
estimated percentage of that cell type present within the total mixed-cell pop-
ulation. Black and white asterisks denote significant p values % 0.05 (*) or 0.01
(**) obtained by two-tailed t test for individual cell types in each infected bat
tissue in comparison to their estimated proportions in uninfected control bats;
colored asterisks correspond to the identically colored cell type below them.
See also Figure S2.
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related genes and IFN regulatory factors (IRFs), which were
mostly induced in CD14+ splenocytes, whereas almost all co-
stimulator upregulation occurred in skin. Colon and liver shared
some viral entry, replication/DNA damage response, and
egress-related antiviral DEGs with skin, including SAMD9L,
poly (ADP-ribose) polymerases (PARPs) and PML, and BST2
(Tetherin), respectively (Table S1). Further, skin and/or CD14+
splenocytes shared induction of MHC-related factors, includingbeta 2-microglobulin (B2M) andHLAs with liver (Table S1), which
may be linked to the recently identified expansion of MHC class I
genes within the ERB genome.18 Lastly, limited sets of DEGs
were unique to and shared among other tissue/cell groupings,
including one DEG each specific to liver (TIGIT), colon
(HSH2D), and spleen (CD163) (Figure S2D; Table S1).
Globally averaged FC levels across datasets were modest:
less than 16-fold in skin (where viral load was highest) and barely
extending beyond 7-fold in CD14+ splenocytes (Figure S2C).
Primary responses were also temporally limited, usually peaking
by D2 (CD14+ splenocytes and whole tissues) or D3 (skin) and
quickly returning to baseline by D5–D8 (CD14+ splenocytes
and tissues) or by D8–D14 (skin) (Figure S2C). Peak responses
occurred within the early exponential phase of viral replication,
just prior tomaximal viral loads (compare Figure S2C to Figure 2).
Significant downregulation, an otherwise rare occurrence seen
at select time points for few DEGs, was observed in spleen at
D8 (Figure S2C).
The Transcriptional Immune Response toMARV in ERBs
Is Characterized by Early and Acute-Phase Induction of
Canonical Antiviral Genes and Pathways Typical of
Mammalian Systems
To better visualize immune response progression in MARV-in-
fected ERBs, we generated heatmaps of nCAA-derived, time
point-averaged DEG datasets (Figures 4 and 5). In addition to
our core analysis of CD14+ splenocytes, skin, and whole tis-
sues (spleen, liver, and colon) in which viral replication has
been previously observed, we separately analyzed antiviral
gene expression in CD19+ splenocytes (Figure S3).3,6 As this
expression profile was largely similar to that found for CD14+
splenocytes, and was presumably indirect as B lymphocytes
are not a known MARV replication target in any species, we
excluded this dataset from comparative analyses in this study.4
Among the five core tissue/cell types, we further discriminated
potential trends by categorizing DEGs into various generalized
response networks with functional roles annotated by
PANTHER and DAVID programs (denoted by color-coded
squares in Figures 4 and 5). The clearest response trend was
a common cluster of 26 DEGs (D2–D5) that accounted for the
most strongly upregulated genes (denoted by asterisks in Fig-
ures 4 and 5); 14 DEGs within the cluster were shared by four
of these tissue/cell types, while the other 12 were upregulated
in all five types. The cluster was dominated by canonical anti-
viral factors usually upregulated in mammalian immune re-
sponses and involved in IFN induction (IRF7, IFI6, XAF1) and/or
antiviral defenses such as pattern recognition (DDX58 [RIG-I],
EIF2AK2 [PKR]), ISGylation (ISG15, HERC5, USP18), the
RNase L pathway (OAS3), and ISG effector functioning (MX1,
IFIT1/2, STAT1).25,28,29,31,38 Some were significantly but tran-
siently downregulated in spleen on D8 (CD163, RIG-I, ISG15,
USP18), most after strong initial induction (Figure 5C). Indeed,
all but one of the three highest-induced genes across tissue/
cell types were cluster DEGs, except late (D14) upregulation
of IL8 in skin, which was the study’s strongest induced gene.
A hierarchy of induction was also noted within the cluster,
particularly ISG15, the leading DEG in liver and colon, among
the top three in spleen and CD14+ splenocytes, and followed
by COMP, OAS1, IFI6, and DHX58 (Figures 4 and 5). TheseCurrent Biology 31, 257–270, January 25, 2021 261
Figure 4. The ERB Transcriptional Immune
Response to MARV Infection in CD14+ Sple-
nocytes
nCAA analyzed differential gene expression (DGE)
using gene counts of infected versus uninfected
bats for CD14+ splenocytes. Selection as a differ-
entially expressed gene (DEG) at each time point
was based on meeting ± 2 fold-change (FC),
p value % 0.05, and above-background count
criteria (described in Methods). At a minimum,
DEGs met these criteria at one or more time points
in each dataset. A heatmap was produced using
Morpheus. Linear FC intensity for each DEG was
denoted in red (upregulation), blue (down-
regulation), or white (no change/failed criteria).
Only datapoints meeting above inclusion criteria
were visualized. Each column denotes a different
time point, as indicated on top of each graph.
Gradient bars represent FC intensity scales, set to
a maximum of 30-fold. Blue asterisks denote the
cluster of 26 canonical antiviral genes common to
at least four of the five major datasets. Color-
coded squares next to most DEGs denote their
functional annotation by PANTHER and DAVID
programs within generalized response networks
as indicated in the bottom legend.
See also Figures S2, S3, and S4 and Tables S1, S2,
S3, and S4.
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across the five tissue/cell types. Despite strong upregulation
relative to other ERB DEGs, cluster gene induction showed
markedly reduced potencywhen compared qualitatively to pre-
viously reported gene induction for NHP homologs in whole
blood, total peripheral blood mononuclear cells (PBMCs), or
PBMC-derived immune cells (including CD14+ monocytes)
following in vivo infection with various MARV or EBOV
isolates.25,28,29,31,39
Complementary heatmaps based on the DEGs identified by
nCAA, inclusive of each infected bat, were also produced (Figures
S4 and S5). Immune response profiles of individual bats within a
cohort were generally very consistent. Further, this analysis re-
vealed broad response intensity differences for individual bats
that correlated with their vRNA levels. The clearest example was262 Current Biology 31, 257–270, January 25, 2021bat #861 (D5), which generally had the
highest viral loads and showed markedly
greater global inductionofDEGs thanother
bats within its time point cohort in CD14+
splenocytes or whole tissues. Collectively,
DEG profiles between nCounter analysis
methods (nCAA-derived versus individu-
ally quantitated) were similar.
Finally, to discern in which main
signaling pathways the DEGs sets may
be involved, we performed Ingenuity
Pathway Analysis (IPA). Two pathways
were unique to CD14+ splenocytes: ‘‘Toll-
like Receptor (TLR) Signaling’’ and ‘‘[DC]
Maturation,’’ the latter of which is ex-
pected for a monocyte-enriched popula-
tion (Figure 6A). IPA of skin featuredentirely unique positively regulated pathways: ‘‘JAK/STAT
Signaling,’’ ‘‘IL6 Signaling,’’ ‘‘IL10 Signaling,’’ ‘‘Th2 Pathway,’’
and ‘‘Role of Macrophages, Fibroblasts and Endothelial Cells in
Rheumatoid Arthritis,’’ potentially selected due to infiltration of
immune cells into the inoculation site (Figure 6B). Strong positive
regulation of IL6, JAK/STAT, and Th2 pathways extended to D28,
perhaps because of virus lingering within the site. CD14+ spleno-
cytes shared two innate immune response pathways with whole
tissues (Figures 6C–6E): ‘‘Activation of IRF by Cytosolic Pattern
Recognition Receptors [PRRs]’’ and ‘‘Role of [PRRs] in Recogni-
tion of Bacteria and Viruses.’’ Two other immune response
pathways were unique to all whole tissues: IFN signaling and
‘‘Role of RIG-I Receptors in Antiviral Innate Immunity.’’ Most
immune response-related pathways showed strong positive
regulation, particularly during early/acute phases (D2–D5).
Figure 5. The ERB Transcriptional Immune Response to MARV Infection in Skin and Whole Tissues
nCAA analyzed DGE as described in Figure 4 for each tissue dataset: (A) skin/inoculation site (across top), (B) liver, (C) spleen,( and D) colon. Heatmaps were
produced as described in Figure 4. Gradient bars represent FC intensity scales, set to a maximum of 30-fold and identical for all datasets except skin (bar at top),
which instead has a maximum of 400-fold. Blue asterisks denote the cluster of 26 canonical antiviral genes common to at least four of the five major datasets.
Color-coded squares next to most DEGs denote their functional annotation by PANTHER and DAVID programs within generalized response networks as
indicated in the center legend.
See also Figures S2 and S5 and Tables S1, S2, S3, and S4.
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Figure 6. A Handful of Canonical Signaling
Pathways Regulated in CD14+ Splenocytes,
Skin, and Whole Tissues Define ERB Tran-
scriptional Immune Responses
Ingenuity pathway analysis (IPA) was used to
determine the top five canonical pathways for each
major dataset: (A) CD14+ splenocytes, (B) skin/
inoculation site, (C) liver, (D) colon, and (E) spleen.
Top five pathways are ranked by p value. Z score
specifies an activation score calculated by IPA
where a positive value indicates that the gene
expression in the dataset is changing in a way that
suggests positive regulation. Negative values
indicate that the gene expression in the dataset is
changing in a way that suggests negative regula-
tion. Pathways without a calculated Z score are
indicated with an ‘‘x.’’
ll
OPEN ACCESS ArticleERB Response to MARV Shows Minimal Regulation of
Cytokine, Chemokine, and Adaptive Immunity-Related
Genes
While ERB immune-related gene induction reflected typical
mammalian responses (albeit with reduced potency than
observed in filovirus-infected NHPs), we wanted to determine if
any DEGs previously identified in MARV-infected spillover hosts
(like NHPs) were not significantly regulated in the natural bat
reservoir.25,38,39 Thus, we compiled all genes within our ERB Co-
deSet not defined by nCAA as significant DEGs (Tables S2, S3,
and S4); these were nearly half the CodeSet’s genes. Many
non-DEGs were signaling intermediates or transcription factors
(Table S2), including those not usually upregulated such as
MAVS, JAKs, STATs, CTNNB1, MAP kinase genes, and MYC.
Other genes unchanged following MARV infection of ERBs
have known involvement in antiviral responses, including
DDX50, IFI35, MX2, OAS2, and UBE2L6. Several innate and/or264 Current Biology 31, 257–270, January 25, 2021adaptive immune response-related gene
markers or receptors, including CD19,
CD8A/B, FOXP3, HLA-A, HAVCR1/2,
and KLRs, were also unaltered (Tables
S2 and S3).
Notably, we observed that many pro-
and anti-inflammatory and receptor
genes, including cytokines, chemokines,
and adaptive immunity-related genes,
were not significantly induced inMARV-in-
fectedERBs (Table S4). Among themwere
most IFN genes, CXCL11, CCL8, CSF2
(GM-CSF); various IL genes such as IL6,
IL33, GZMA, and NOS2/3; and receptors
including CD40, FAS, IFNAR1, and IL6R.
To further clarify the impact of the mini-
mally regulated cytokine and chemokine
signaling/receptor pathway in CD14+
splenocytes and skin of infected ERBs,
we usedPathviewWeb to visualize regula-
tion of over 80 DEG and non-DEG
pathway members present in the ERB
CodeSet. The lack of significant cytokine,
chemokine, or receptor induction identi-fied by Pathview was remarkable. In CD14+ splenocytes, cyto-
kine induction was mostly limited to the overall modest D1
response, with strongest but transient induction of IL8, IL1A/B,
and TNF (Figure 7). In skin at the inoculation site, where presence
of these inflammatory response factors is expected due to the
high viral load at this location following MARV inoculation, only
a handful were identified as significantly upregulated, particularly
IL8, IL1B, CXCL10 (IP10), CCL5 (RANTES), and CCR5 (Fig-
ure S6A). Few additional genes with any role in inflammation as
annotated by PANTHER and DAVID programs were induced
beyond low, often transient levels, including TNFAIP3 (CD14+),
ICAM1, and LGALS9 (CD14+ and skin) and CXCL2, S100A12,
and ZBP1 (skin) (Figures 4 and 5). Overall, inflammatory re-
sponses contrasted with those for other antiviral pathways such
as RIG-I, TLR, and TNF signaling, which showed significant
DEG involvement in skin and CD14+ splenocyte datasets during
early/acute phases of MARV infection (Figures S6 and S7).
Figure 7. ERB Transcriptional Immune Responses Occur in the Absence of Significant Expression Changes for All but a Few Cytokine and
Chemokine Signaling/Receptor Genes
Pathview Web analysis shows representative DGE of the cytokine/chemokine receptor interaction pathway for CD14+ splenocytes. Genes in white boxes are
those without ERB CodeSet probes; genes in greyed boxes are those represented in the CodeSet. Red bands indicate upregulation of a given gene, blue bands
indicate downregulation, and gray bands indicate lack of expression change/failed inclusion criteria; each band indicates a different post-infection time point
from D1 to D28, arranged left to right across a gene box. Legend at top right defines color intensity scale set at indicated log2FC values.
See also Figures S6 and S7 and Table S4.
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Soon after the discovery of MARV, key questions quickly
emerged, including what the natural reservoir is, how the virus
spills over into humans and NHPs, and importantly, how does
the reservoir host immunologically control the pathogen while al-
lowing sufficient viral replication to enable transmission.1,2,5,6,11,15
In this report, we characterize the in vivo transcriptional immune
response in MARV natural reservoir, focusing on CD14+ spleno-
cytes and skin at the inoculation site, both pathogenesis-relevant
sites of virus replication.
DGE analysis across tissue datasets revealed a broad, distinc-
tive host response in which inflammatory genes and their recep-
tors were not significantly changed in MARV-infected ERBs, in
stark contrast to the extensive dysregulation seen in pri-
mates.7,27–29,31,39 While we cannot completely rule out nonca-
nonical strategies by which some non-DEGs could contribute
to MARV resistance (e.g., enhanced basal expression that
‘‘primes’’ ERBs to better engage antiviral defenses, as demon-
strated in Pteropus bats), this transcriptional phenotype offers
the first in vivo functional evidence for disease tolerance in afilovirus reservoir.11,12,14–16 In this scenario, the antiviral state in
MARV-infected ERBs would restrict replication while avoiding
immune-mediated pathology caused by cytokine and chemo-
kine dysregulation. Thus, the absence of DEGs thought to cause
such pathology is remarkable and holds at least three major im-
plications regarding the differences in pathogenesis between in-
fected reservoirs and accidental spillover hosts and the exact
physiological avenues by which reservoirs and viruses co-
evolved a tolerant host environment. First, the paucity of signifi-
cant cytokine/chemokine responses in ERBs is clearly distinct
from those observed in filovirus-infected primates and relates
to disease burden.7,8,27,28,30,31 Only a handful of such genes
(including CCL5, IP10, IL1B, IL8, and TNF) were significantly up-
regulated either at the infection site or transiently in CD14+ sple-
nocytes and almost none in whole tissues, consistent with previ-
ous clinical observations of minimal tissue inflammation in
ERBs.3,6 Non-DEG cytokines/chemokines within the ERB Code-
Set includedmost IFNs, ILs such as IL12B and IL33, NOS genes,
and a few CCLs, CCRs, and CXCRs. Indeed, recently published
in vitro data from our lab using MARV-infected ERB BMDCs also
showed limited inflammatory gene regulation, expandingCurrent Biology 31, 257–270, January 25, 2021 265
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distinction between our current in vivo-based work and the
BMDC study was that IL33 was strongly suppressed in BMDCs,
which might simply suggest DC-specific gene regulation. Mean-
while, the lack of significant induction of IFNs agrees with previ-
ous data from an ERB kidney cell line even after being infected
with a recombinant MARV ablated in its usual ability to antago-
nize IFN-mediated antiviral gene induction via VP35, and despite
those cells showing marked induction of multiple IFN genes by
an unrelated control virus (Sendai virus).19 Type I IFN genes
also showedminimal, if any, detectable basal gene counts in un-
infected bats, suggesting that ERBs do not rely on constitutively
activated IFN as posited for P. alecto bats by Zhou et al.12 It is
tempting to speculate that IFN-independent responses therefore
occur in these animals, allowing induction of specific antiviral
genes even in the presence of viral antagonist proteins. For
instance, recent work by the Mühlberger lab showed that
MARV VP35 inhibits PKR in human but not ERB cells, and there
is precedent for IFN-independent response induction by IRF3 or
STAT1 of subsets of canonical antiviral genes during in vitro hu-
man cytomegalovirus (HCMV) infection.40–42 This does not pre-
clude, however, the alternative possibilities that induction of
IFN gene transcription simply occurs at levels too low for
nCounter to detect, certain IFN proteins are activated on a
post-transcriptional level, and/or the ability of MARV proteins
to fully suppress IFN is cell type-dependent, any of which would
suggest that IFNs still act as master antiviral response regulators
in MARV-infected ERBs, perhaps in a paracrine fashion, without
a need for noncanonical explanations. Of most relevance to
pathogenesis among the cytokine/chemokine non-DEGs in
ERBs is that they appear to be largely pro- or ambi-inflammatory;
several are highly induced in primate filoviral infections, including
IFNg, IL2, IL4,MIP-1b (CCL4), andCSF2.8,24,25,27,30,31,39 Indeed,
CCL8, FAS, and particularly IL6 are commonly reported hall-
marks of the primate inflammatory response and subsequent se-
vere disease.24,27,39 While basally expressed in naive ERBs,
none of these genes displayed any significant activation upon
MARV infection, suggesting no role in the ERB response to
MARV, again consistent with a disease tolerance model.11,14–16
Second, tolerance may offer a molecular explanation for why
these bats have previously exhibited non-neutralizing antibody
activity when tested in vitro and rapidly waning IgG in serum
despite protective secondary responses upon MARV rechal-
lenge.43 Our data show insufficient adaptive immune gene in-
duction (such as AGER, CD40, HLA-A, IL13, and TNFSF13)
that could be associated with unique mechanisms dictating
lymphocyte maturation, Ig structure/function and/or memory
cell generation/activity. Prior genomic studies have posited
that in some bat species, there is a diminished emphasis on
the role of somatic hypermutation, which could subsequently
lessen a role for IgG during primary acute infection and poten-
tially promote dampened antibody-mediated inflammation.10
Our results extend the possibility of quantitatively reduced adap-
tive immunity to ERBs on a transcriptional level. We also identi-
fied (likely indirect) antiviral gene expression in CD19+ spleno-
cytes following MARV infection, possibly affecting the role of B
cells in adaptive immune processes, as well as a conspicuous
proportional reduction of skin and spleen B cells in our
CIBERSORT analysis. This latter data suggest depletion of266 Current Biology 31, 257–270, January 25, 2021lymphocytes from these tissues at around or just prior to when
MARV-infected ERBs exhibit initial IgG production, which could
possibly further contribute to the IgG response phenotype and/
or reduced antibody-mediated inflammation.4–6,44 Given these
open questions, a better understanding of antibody loci, devel-
opment, and response in these animals is required. Third, this
finding offers insight into the broader spectrum of antiviral
response strategies used by viral reservoir hosts in vivo, and
into how disease tolerance in ERBs compares to other host-virus
relationships. This relationship has been well characterized for
hantavirus rodent hosts. Like ERBs, bank voles (Myodes glareo-
lus), male Norway rats (Rattus norvegicus), and deer mice (Pero-
myscus maniculatus) infected with Puumala virus, Seoul virus, or
Sin Nombre virus, respectively, show no clinical signs of disease,
lack tissue-specific proinflammatory cytokine induction, and
generate low or non-neutralizing antibody responses.45–48
Disease tolerance has also been suggested in studies with rac-
coons infected with raccoon rabies virus and mallards infected
with low-pathogenic H1N1.49,50 However, to our knowledge,
no other significant in vivo study of broad transcriptional immune
responses in any bona fide bat reservoir has been performed.
Coronavirus inoculation of a suspected but unconfirmed ances-
tral reservoir, the Jamaican fruit bat (Artibeus jamaicensis), re-
sulted in subclinical disease and transient, low-level induction
of MX1, IFIT1, and RANTES, supporting tolerance.51 More
recently, a second, proteomics-based study compared the
lungs of Hendra virus-infected P. alecto bats and ferrets 60 h
post-infection, in conjunction with limited IFN and cytokine
TaqMan analysis.52 This report found downregulation of consti-
tutively expressed IFN in these bats, with a significantly more
likely enhancement of IFN signaling and neutrophil-, T cell-,
and antibody-mediated immunity pathways than ferrets, sug-
gesting inflammatory response suppression amidst concomitant
cell-mediated response activation. These two studies, however,
remain rare examples of in vivo immune response data for bats.
Intra-order comparisons beyond gross clinical observations thus
remain challenging, highlighting the necessity for expanded
in vivo reservoir host research to capture a more comprehensive
and contextual picture of the complex biological processes that
follow infection by pertinent pathogenic threats like filoviruses.
The overarching immunological principles and precise host fac-
tors dictating reservoir protection against disease that such
studies uncover have become essential in a globalizing world
where human contact with wild hosts, and emerging disease
outbreaks from the viruses they harbor, becomes an ever more
frequent event, as the likely recent spillover of SARS-CoV-2
from an unidentified bat reservoir has illustrated to a profoundly
devastating effect.
DGE analysis also revealed commonalities and differences
between significant ERB and primate responses, as well as the
potential importance of several specific DEGs. MARV infection
of ERBs stimulated canonical immune response genes, such
as ISG15, IFIT2, RIG-I, and OAS1.28,38 Similar upregulation
was not seen previously using MARV-infected ERB cell lines;
rather, antiviral genes were largely suppressed.19 The apparent
discrepancy in immune gene signaling between infected cells
and whole animals has also been reported in primate studies,
again emphasizing the value of investigating in vivo host re-
sponses.24 This phenotypic disagreement between in vitro and
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mentioned viral antagonists like VP35, which at high multiplicity
of infection common for in vitro assays could accentuate sup-
pressive antagonist abilities (another potential explanation for
the lack of significant IL33 induction in vivo compared to
BMDCs).19,21,53 Further, their functions could be restricted
temporally or by cell type and/or unresolvable in mixed cell pop-
ulations. Indeed, primate macrophages, a primary filoviral target,
show robust antiviral gene responses both in vitro and in vivo
following EBOV infection, as do the ERB-derived BMDCs after
ex vivoMARV infection, both reflecting those we observed in vivo
in MARV-infected ERB CD14+ splenocytes.21,24,25 Comparing
in vivo data from our work using the ERB-derived MARV isolate
371Bat2007 to data from filoviral primate studies is vital to under-
standing how the natural reservoir has evolved to better control
infection compared to the maladaptive immunopathology eli-
cited in primate spillover hosts. For instance, most MARV pri-
mate experiments use the Musoke or Angola virus isolates
that, at the whole-genome level, are 93% identical to each
other and 92% identical to 371Bat2007. Importantly, each of
these viruses is linked to, or isolated from, fatal human infections
and causes near-uniformly fatal disease in NHPs. Indeed, the
MARV bat isolate used in our study is greater than 99% identical
to 01Uga07, a virus isolated from a fatally infectedminer working
at Kitaka mine in Uganda where the ERB harboring 371Bat2007
was captured.26,54 Therefore, the high degree of sequence
identity between 371Bat2007 and 01Uga07, combined with the
known diversity among fatal human filoviruses, strongly sug-
gests that this bat isolate would also cause severe, if not
lethal, disease in primates. To this end, DEGs in MARV-infected
ERBs consisted of canonical antiviral genes typical of those seen
in infected primates and other mammalian systems.25,28,29,31,38
Most, if not all, of the 26 cluster DEGs common across ERB tis-
sues/cells, such as ISG15,OAS1, andMX1, have also been iden-
tified as elevated in MARV-infected primates.25,29,31 Moreover,
cluster DEGs acted within a limited spectrum of traditional path-
ways shared by primates and other bat species, such as OAS/
RNase L signaling, ISGylation, and JAK/STAT signaling.13,25,31,53
Assuming these ERB genes have antiviral capabilities akin to
their primate orthologs, this implies that cluster gene induction
alone does not confer MARV protection to ERBs, as we hypoth-
esized in our ERB kidney cell line-based study.19 However, these
data suggest that antiviral responses are better regulated in
ERBs than in primates, with a subset of genes dictating a large
proportion of the global response but confined to a short-lived in-
duction window in which these presumably normal responses
are actively controlled. Further, ERB response genes were
substantially less induced than those previously measured in pri-
mate whole blood, monocytes, or tissues.25,29,31,39 For a prob-
able ERB infection target like CD14+ splenocytes to showmostly
as limited, tightly regulated, and canonical a response profile as
ERB whole tissues, whereas in primates these immune cells
show extensive, strong ISG, and adaptive immune and
inflammatory gene responses, is perhaps also indicative of dis-
ease tolerance.25 Among non-cluster DEGs, some showed
notable changes. The intense mid/late upregulation of IL8,
IL1B, and S100A12 at the skin inoculation site was possibly
due to an uncleared bolus of virus and/or prolonged immune
cell infiltration. Conversely, several DEGs downregulated D2–D3 in skin and spleen play roles in transitional innate-adaptive
processes, including T cell activation by DCs (DC-SIGN, also a
filovirus receptor), NK cell recognition of MHC class I molecules
(KLRC1 [NKG2]), T cell activation via MHC class II-presenting B
cells (TMEM173 [STING]), and monocyte-macrophage differen-
tiation (CD14). Suppressing these factors could impact estab-
lished downstream features of MARV pathogenesis, such as
lymphopenia due to lack of DC maturation and T cell activation
(which itself modulates antibody production).4,7,8
Another notable aspect of our study was an ability to correlate
MARV replication levels with specific ERB immune response
gene kinetics across tissue/cell types, including at early and
acute time points post-infection, thereby greatly expanding
upon previous work that was able to detect only MARV RNA in
these tissues.3,6 Indeed, virus disseminated quickly from the
inoculation site, evidenced by virus positivity in spleen and liver
by D1 and corresponding broad early host gene induction in
skin and CD14+ splenocytes. This D1 response in CD14+ spleno-
cytes occurred prior to responses in the surrounding spleen tis-
sue. These kinetics leave open the likely possibility that infiltrating
monocytes may be initially infected at the inoculation site and
then transport the virus into the spleen and other tissues. Thus,
CD14+ splenocyte response induction following infection, repli-
cation, and viral protein expression is likely critical to MARV path-
ogenesis, irrespective of infectious virion formation from this cell
type (not specificallymeasured in the context of this study), which
might very well guide toward a non-productive infection given a
fully functional, co-evolved ERB immune system capable of miti-
gating viral disease burden. Further, since B lymphocytes are not
known to be MARV replication targets, any observed antiviral
gene transcription in CD19+ splenocytes is likely due to paracrine
induction by host factors secreted from these early infected
spleen monocytes.4 Indeed, as the majority of total splenocytes
(56%) consisted of CD14+ andCD19+ cells and expression pro-
files were largely similar between them, upregulation of their
DEGs probably formed the basis of the overall response seen
for whole spleen. Despite the early kinetics in skin and CD14+
splenocytes, onset of the bulk of the host response was delayed
until D2. Responses correlated with viral load through D5. As
identified by CIBERSORT in the skin and spleen, kinetics of viral
loads and/or immune responses also corresponded to propor-
tional, in some cases significant, estimated changes in lympho-
cyte and macrophage populations indicative of cell depletion/
apoptosis and activation/infiltration, respectively (although we
must caveat that this analysis is based solely on gene expression
data from our large, though finite, ERB CodeSet and will need
validation in future studies in order to rule out possible biases
due to reliance on nCounter values or human-specific marker
gene signatures). Nevertheless, together these observations sug-
gest that innate immunity in ERBs, capable of robust upregulation
even during peak infection, swiftly controls viral replication,
possibly without substantial lymphocytic support. Simulta-
neously, negative feedback pressures (e.g., USP18, a known
IFN signaling modulator) coordinate equally rapid cessation of
primary gene responses once virus control is secured. The corre-
lation of viral replication to host response also implies proportion-
ality in individual bats. For example, as seen in bat #861, high viral
load may be linked to transcriptional ‘‘superinduction’’ and
immune cell population phenotypes. This putative relationshipCurrent Biology 31, 257–270, January 25, 2021 267
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bats under stressful or immunomodulating conditions permit
greater viral replication), immune adaptability (whether bat
response gene expression equalizes with viral yield as needed),
and virus maintenance (how these higher yields and stronger re-
sponses affect viral shedding and transmission potential) and
therefore warrants further exploration. Additionally, as previous
data suggest that bat-to-bat transmission could occur through
biting (i.e., subcutaneous inoculations in skin), future studies
focused on the subcutaneous skin inoculation site are of particu-
larly high biological relevance for understanding MARV replica-
tion and control in nature.5,6
In conclusion, we hypothesize a refined model for disease
tolerance to MARV infection in its bat reservoir. This model is
defined by tissue-wide, moderate stimulation of canonical anti-
viral genes early in MARV infection, possibly relying on putative,
noncanonical mechanisms (like IFN-independent induction) to
finely calibrate a cluster of the innate immune response with
rheostat-like precision. ERBs may thus have evolved to suc-
cessfully disrupt viral replication without an evolutionary
emphasis on adaptive responses for long-lived immunity or
without triggering uncontrolled inflammatory gene expression
responsible for the classical ‘‘cytokine storm’’ and subsequent
severe immunopathology characterizing MARV disease in
primates, including humans. Moving forward, it will be of para-
mount interest to elucidate the gene functions, molecular
mechanisms, and immune cell types that mediate this disease
tolerant phenotype following MARV infection, which may in
turn be applicable to bat reservoir hosts of other emerging path-
ogens and translate into novel spillover control or antiviral ther-
apeutic strategies that better protect humans from zoonotic
viral infection and pathogenicity.STAR+METHODS
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Rat monoclonal anti-CD19 (ERB) USAMRIID/Aldevron,
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N/A
Rat IgG-PE Isotype Control Abcam Cat#ab37368
Bacterial and Virus Strains
MARV strain 371Bat2007 Albariño et al.26 GenBank: FJ750958.1
rMARV371-ZsG Albariño et al.36,37 N/A
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ERB tissue-, cell- and blood-derived total RNA This paper N/A
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MagMAX RNA Lysis/Binding Solution Concentrate Thermo Fisher Scientific SKU#AM8500
Benzonase Nuclease HC, Purity > 90% EMD Millipore Cat#71205-3
ACK Lysing Buffer GIBCO, Thermo Cat#A1049201
LIVE/DEAD Fixable Aqua Dead Cell Stain Kit Invitrogen, Thermo Cat#L34966
autoMACS Rinsing Solution Miltenyi Biotec Cat#130-091-222
MACS BSA Stock Solution Miltenyi Cat#130-091-376
Normal Rat Serum Thermo Cat#10710C
Anti-PE MicroBeads UltraPure Miltenyi Cat#130-105-639
Cytofix/Perm Buffer BD Biosciences Cat#554722




Lightning Link R-PE Conjugation Kit Expedeon, Abcam Cat#ab102918
Geno/Grinder 2000 Homogenizer SPEX SamplePrep N/A (Discontinued)
Spleen Dissociation Kit (mouse) Miltenyi Cat#130-095-926
gentleMACS Octo Dissociator with Heaters Miltenyi Cat#130-096-427
MACS MicroBead system w/ MultiMACS Cell24
Separator Plus
Miltenyi Cat#130-098-637, Cat#130-095-691





MagMAX Pathogen RNA/DNA Kit ABI, Thermo Cat#4462359
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nCounter Reporter ERB CodeSet NanoString, Prescott et al.21 N/A
nCounter Capture ERB ProbeSet NanoString, Prescott et al.21 N/A
nCounter SPRINT Cartridge NanoString Cat#SPRINT-CAR-1.0
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(Uganda origin)
Amman et al.6 N/A
Oligonucleotides
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Amman et al.6 N/A
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FlowJo v10 FlowJo, LLC https://www.flowjo.com/solutions/flowjo/downloads





CIBERSORT Stanford University https://cibersort.stanford.edu/




GraphPad Prism v7.0 and v8.3.1 GraphPad Prism
Software, Inc.
https://www.graphpad.com/scientific-software/prism/
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Further information and resource requests should be directed to and will be fulfilled by the Lead Contact, Jonathan S. Towner (jit8@
cdc.gov).
Materials Availability
This study did not produce new unique reagents.
Data and Code Availability
The published article includes all datasets analyzed during the study (see Data S1 and S2).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Work with 2nd- and 3rd-generation, captive-born ERBs (Rousettus aegyptiacus) from our colony of bats originally imported from
Uganda was approved by the Centers for Disease Control and Prevention (CDC) Institutional Care and Use Committee (IACUC)
in conjunction with the Animal Care and Use Review Office (ACURO) of the U.S. Army Medical Research and Materiel Command
(USAMRMC). Work was conducted strictly following the Guide for the Care and Use of Laboratory Animals. CDC is accredited by
the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). This study was a 28-day se-
rial time course, conducted at biosafety level 4 (BSL-4) conditions, designed to investigate immune responses, via transcriptomic
analysis, following inoculation of ERBs with MARV. 40 healthy juvenile (seven-month old) male and female ERBs were randomly
assigned to one of eight cohorts, five bats per cohort. One cohort was euthanized 1, 2, 3, 5, 8, 13 (uninfected control bats), 14 and
28 days post-inoculation. ERBs were acclimated to the BSL-4 lab two weeks prior to inoculation. Each bat cohort was housed in
cages in separate isolator units with HEPA-filtered inlet and exhaust air supplies (Duo-Flow Mobile Units, Lab Products, Inc. Sea-
ford, DE, USA). Husbandry procedures were conducted daily, including housing in climate-controlled animal area within the BSL-4
lab, a 12 h day/night light cycle, routine animal room cleaning and animal observation, and daily provision of fresh fruit (body mass




Work with infectious agents and infected animals was conducted at CDC (Atlanta, GA, USA) in a biological safety level 4 (BSL-4) lab-
oratory in agreement with Select Agent protocols and practices (https://www.selectagents.gov). Researchers and animal care staff
worked in accordance to BSL-4 level safety principles and adhered to proper infection control procedures to prevent cross contam-
ination between bat cohorts. All animal handling was performed with leather bite gloves, with disposable latex gloves worn over the
bite gloves when directly conducting animal procedures.
Viruses and antibodies
Inoculations were performed with MARV strain 371Bat2007 (GenBank: FJ750958.1), originally isolated from a naturally infected ERB
caught at Kitaka Mine in Uganda in 2007 and passaged twice on Vero-E6 cells.26 Separately, for ex vivo infection of CD14+ spleno-
cytes from naive colony ERBs to validate monocyte infectivity, we used a recombinant version of MARV 371Bat2007 that expresses
ZsGreen (rMARV371-ZsG), which acts as a marker of successful filoviral replication.21,26,36,37 ERB-specific monoclonal antibodies
against CD14 and CD19 were custom-generated in partnership with USAMRIID. In brief, CD14 and CD19 target sequences were
identified in the ERB genome and their extracellular domains cloned into a surface expression vector. This construct was sent to Al-
devron, LLC (Fargo, ND, USA), where rats were immunized using a proprietary Genetic Immunization protocol. B cells from immu-
nized rats were fused to generate hybridoma cells and further tested for reactivity toward either CD14 or CD19 using fast enzyme-
linked immunosorbent assay (F-ELISA). For each target, the top 10 hybridomas were subcloned and retested using the same meth-
odology. The top three hybridomas were sent to USAMRIID, where purified rat IgG from each hybridoma supernatant was pre-con-
jugated to various fluorophores via the Lightning Link Antibody Conjugation Kit system (Expedeon, Abcam, Cambridge, MA, USA)
and further tested and optimized using P. vampyrus and ERB PBMCs by flow cytometry. The single top-performing monoclonal an-
tibodies for CD14 and CD19 were selected by cell staining and plot profiling. Finally, prior to initiation of the bat study, the two vali-
dated antibodies were pre-conjugated to PE via the Lightning Link R-PE Kit.
Inoculations and sampling
Infections were performed as previously described in:3,6 under isoflurane anesthetic, bats were inoculated subcutaneously in the
ventral abdomen with 104 TCID50 of MARV (250 mL of 4 3 10
4/mL) in sterile Dulbecco’s Modified Eagle’s Medium (DMEM, GIBCO,
Thermo Fisher Scientific, Waltham, MA, USA), while control bats were mock-inoculated with an equal volume of DMEM alone. This
viral dosage, which is lethal in NHPs, has been shown to recapitulate the tissue tropism and viral load seen in natural ERB infections,
including their lack of clinical disease, and is the inoculum our lab has adopted across several previous bat studies in order to main-
tain data consistency.5,6,60,61 To measure MARV RNA levels in whole blood over the course of the experiment, 20mL samples from
each bat for RNA isolation were taken pre-inoculation, then daily post-inoculation until euthanasia, by venipuncture of the cephalic
vein on the propatagium of alternating left/right wings using a sterile lancet (C&A Scientific, Manassas, VA, USA). Blood samples were
placed directly into 130mL of 1 3 MagMAX RNA Lysis/Binding Solution (Applied Biosystems [ABI], Thermo) in a deep well plate.
Euthanasia and necropsy
Each bat cohort was euthanized under deep isoflurane anesthesia by exsanguination via cardiac puncture just under the xyphoid
process, followed immediately by post-mortem necropsy. Tissues collected included liver, spleen, skin at the inoculation site and
colon/rectum. Roughly 100mg tissue sections were collected for RNA isolation by placing them into 2mL grinding vials (OPS Diag-
nostics, Lebanon, NJ, USA) with 1mL of MagMAX RNA Lysis/Binding Solution Concentrate and homogenized for two minutes at
1500 strokes/min using a ball-mill tissue grinder (Geno/Grinder 2000, SPEX SamplePrep, Metuchen, NJ, USA). Additional spleen
sections were processed into single-cell suspensions. Separately, naive colony bats were euthanized as above, and spleens har-
vested and processed for microscopy-based ex vivo validation of total splenocyte, CD14+ and CD19+ populations as well as
rMARV371-ZsG infection of CD14+ splenocytes.
Cell preparation
Single-cell suspensions were produced by placing approximately half a spleen into a gentleMACS C tube (Miltenyi Biotec, Bergisch
Gladbach, Germany), pre-loaded with 2.5mL Spleen Dissociation Kit (mouse) enzymemix (Miltenyi) prepared according to manufac-
turer’s instructions. Sealed C tubes were run on a gentleMACS Octo Dissociator with Heaters (program 37C_m_SDK_1). Roswell
Park Memorial Institute (RPMI, GIBCO, Thermo) medium supplemented with 10% fetal bovine serum (FBS, HyClone, Cytiva Life Sci-
ences,Marlborough,MA, USA), 1%Pen-Strep (GIBCO, Thermo) and 1:10000 Benzonase Nuclease HC (250U/mL, purity > 90%, EMD
Millipore, Billerica, MA, USA) were added to cell suspensions, passed through 70 mmstrainers into conical tubes and spun at 3503 g.
Pellets were resuspended in ACK Lysing Buffer (GIBCO, Thermo) and incubated at room temperature with periodic inversion. Cells
were washed and resuspended in RPMI/Benzonase, then enumerated using aMOXI ZMini cell counter (ORFLO, Ketchum, ID, USA).
Cell labeling and magnetic selection
Splenocytes were subjected to 1) antibody labeling for flow cytometric validation; 2) enrichment for CD14+ or CD19+ cell populations
via labeling and themagnetic-activated cell sorting (MACS)MicroBead system (Miltenyi) for RNA lysis; and 3) a combination of MACSCurrent Biology 31, 257–270.e1–e5, January 25, 2021 e3
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ing only, 1-2 3 106 splenocytes in 96-well round bottom plates were washed in Dulbecco’s phosphate-buffered saline (D-PBS,
Sigma-Aldrich, MilliporeSigma, St. Louis, MO, USA) and stained using the LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen,
Thermo). ForMACS, up to 13 107 splenocytes in 96-well plates were washed in autoMACS buffer (MACSBSAStock Solution diluted
1:20 in autoMACS Rinsing Solution, Miltenyi). For both procedures, cells were then blocked in D-PBS supplemented with 2% rat
serum (D-PBS + RS, Thermo) prior to addition of D-PBS + RS containing CD14-PE or CD19-PE antibody. Labeled cells were washed
and resuspended in D-PBS (for labeling alone) or, alternatively, washed in autoMACS buffer, incubated with anti-PE UltraPure Mi-
croBeads and magnetically selected through 24-well column blocks in a MultiMACS Cell24 Separator Plus via either the POSSEL
or POSSEL2 programs followingmanufacturer guidelines (Miltenyi). CD14+ and CD19+ splenocytes were then aliquoted for RNA lysis
or flow analysis, while ex vivo total splenocytes or MACS-selected immune cells from naive colony ERBs were placed in 24-well
plates and observed by microscopy using the EVOS FL Cell Imaging System (Thermo) after a one- or two-day incubation at 37C
to confirm cell morphology and homogeneity followingMACS. Validation of labeling/MACS also included a rat IgG-PE isotype control
(Abcam) and MACS negative fractions. Samples for flow cytometry were incubated in CytoFix/Perm buffer (BD Biosciences, San
Jose, CA, USA) for at least 20 min. Prior to cytometric analysis, fixative was replaced with D-PBS + 2% FBS (STEMCELL Technol-
ogies Inc., Vancouver, BC, Canada). Samples were run on a Stratedigm S1000EX cytometer (San Jose, CA, USA) and data was
analyzed using FlowJo version 10 (FlowJo, LLC, Ashland, OR, USA).
Ex vivo CD14+ splenocyte infectivity assay
CD14+ splenocytes from naive colony ERBs were placed into 5mL tubes, infected with rMARV371-ZsG at amultiplicity of infection of
0.5 and incubated at 37C. After a 1 h adsorption, cells were spun and resuspended in fresh 10%RPMI + antibiotics, and then placed
onto 24-well plates and re-incubated. ZsG fluorescence representing successful MARV replication in cells characteristic of mono-
cytes/macrophages was visualized at D1, D2 and D3 by EVOS microscopy.
RNA isolation and TaqMan assay
Tissues, CD14+/CD19+ splenocytes and whole blood were lysed to inactivate virus using MagMAX RNA Lysis/Binding Solution with
(blood and cells) or without (tissues) a 1:1 ratio with 100% isopropanol and removed from biocontainment. Total RNA was extracted
by magnetic bead purification using either (for tissues) the MagMAX-96 Total RNA Isolation Kit with TURBO DNase treatment set for
the AM1830_DW protocol or (for blood and cells) the MagMAX Pathogen RNA/DNA Kit (no DNase treatment) set for the
AM1836_DW_50v2 (blood) or 4462359_DW_HV (cells) protocol, all run in a MagMAX Express-96 Deep Well Magnetic Particle Pro-
cessor (ABI, Thermo). For tissues, each reaction used 125mL of lysate with 75mL of 100% isopropanol. RNA yield was assessed by
NanoDrop (Thermo) as needed and stored at 80C. Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) of
whole blood or liver/spleen was conducted using the SuperScript III Platinum One-Step qRT-PCR Kit (Thermo) via TaqMan
primers/probes against MARV VP40 and run on an ABI 7500 Real-Time PCR System (Thermo) in tandem with 7500 Software
v2.0.6. Relative TCID50 equivalents per mL (blood) or g (tissues) were inferred from existing standard curves as described in,
3 which
were generated from ten-fold serial dilutions of MARV stocks used for bat inoculations that had been added to blood or tissue (calf
liver) homogenate in the same manner as experimental samples.
nCounter hybridization and count detection
Hybridization reactions using a custom ERB-specific nCounter CodeSet (NanoString Technologies, Seattle, WA, USA) were per-
formed on 12 samples per run according to manufacturer’s instructions: 70mL hybridization buffer with or without RNase-free water
was mixed with each Reporter CodeSet reagent, aliquoted into PCR tubes, mixed with up to 5mL, or in certain instances up to 8mL, of
total RNA from ERB tissues or CD14+/CD19+ splenocytes, and finally mixed with each Capture ProbeSet reagent. Samples were
pulse-spun, incubated for 24 h at 65C in a T100 thermal cycler (Bio-Rad, Hercules, CA, USA), re-spun, brought up to 32mL
each with RNase-free water, mixed and 30mL loaded onto an nCounter cartridge for data collection using a SPRINT Profiler loaded
with the BAT_IR_Panel_2_C6075 CodeSet Reporter Library File.
QUANTIFICATION AND STATISTICAL ANALYSIS
ERB probe-based nCounter CodeSet
A probe-based nCounter CodeSet targeting 380 ERB-specific immune genes, along with 10 probes targeting MARV (GenBank:
FJ750958.1) transcripts, was designed under contract by NanoString using the Raegyp2.0 genome assembly (RefSeq:
GCF_001466805.2) and the NCBI R. aegyptiacus Annotation Release 100 (Data S1 and S2).19,21 Following initial analyses, six genes
showed ubiquitous borderline or below-background count threshold levels across tissue/cell datasets: IFI44, IFITM2, IL12A, IL21, IL3
and TLR9. As differentiation between non-expression versus probe failure was not possible, these targets were removed from final
analysis. IFN genes were exempted from exclusion due to known vagaries in IFN induction.
nCounter transcriptomic analysis
Data were processed by nSolver 4.0 (NanoString). After quality control of RCC files, raw counts in each complete dataset were
normalized to geometric mean counts of synthetic positive controls (included in the CodeSet) to mitigate platform-based variation.e4 Current Biology 31, 257–270.e1–e5, January 25, 2021
ll
OPEN ACCESSArticleDue to failed quality control or positive controls, select bat samples were removed from analysis: bat #557 (control cohort) for liver,
#906 (D1) for spleen, #509 (D2) for CD14+ splenocytes, and #139 (control) and #624 (D28) for colon. Using the nCAAmodule (version
2.0.115), the geNorm algorithm normalized each dataset by selecting the fivemost stable ERB genes as housekeepers. Housekeeper
sets varied and are listed in Data S1. nCAA computed DGE in the context of each complete dataset (using the ‘‘Optimal’’ setting) by
comparing gene counts from infected bats at each time point to counts of corresponding genes from uninfected bats. Relevance,
significance and count threshold criteria for DGE analysis at each time point were set to minimums of ± 2 FC, Benjamini-Yeku-
tieli-adjusted p value% 0.05 and above-background count threshold (i.e., genes deemed truly expressed) of 23 standard deviation
(SD) of themean count of all synthetic negative controls (included in the CodeSet) across all samples. All criteria were simultaneously
required at one or more time point for a gene to be considered a bona fide DEG. For nCAA-based DGE analysis, only DEG values
meeting these criteria were included in data visualization. Statistical information for DGE can further be found in figures and figure
legends. For MARV quantification in skin, normalized viral gene or vRNA counts from each infected or control time point cohort
were averaged and standard error assigned as noted in figures and figure legend; as bat #861 was the only animal with MARV
gene and vRNA counts above background threshold in CD14+ splenocytes, averaging or standard error determination was not
possible for this dataset. Count and DGE data can be found in Data S1 and S2 files.
CIBERSORT analysis
Normalized log2 counts of all NanoString ERB CodeSet gene probes, for each tissue/cell type at each time point for each individual
bat, were uploaded for analysis by web-based Cell-type Identification by Estimating Relative Subsets of RNA Transcripts (CIBER-
SORT, https://cibersort.stanford.edu/, Stanford University, Stanford, CA, USA). Analysis was run using a reference set of 22 immune
cell subtypes (LM22) and run for 100 permutations. Cell subtypes were combined into the following general types: neutrophils, eo-
sinophils, mast cells, dendritic cells, macrophages, monocytes, NK cells, T cells and B cells for graphing. Individual bats were aver-
aged for each time point for summary graph figures. A two-tailed t test using individual bats as replicates was performed to determine
statistical significance between cell types and time points as compared to uninfected (D13 NEG) control bats using GraphPad Prism
(GraphPad Prism Software, Inc., La Jolla, CA, USA). Graphs were also created using Prism. Statistical information for CIBERSORT
can further be found in related figures and figure legends where applicable.
Gene Ontology (GO) and pathway analysis
Functional annotation of all DEGs into general response networks was performed via GO analysis using both the web-based Data-
base for Annotation, Visualization and Integrated Discovery (DAVID, https://david.ncifcrf.gov/, Frederick National Laboratory for
Cancer Research, Frederick, MD, USA) and Protein Analysis Through Evolutionary Relationships (PANTHER, http://www.
pantherdb.org/, University of Southern California, Los Angeles, CA, USA) programs.55–57 Homo sapiens was used as the annotation
species. The GOTERM_BP_DIRECT was used to categorize genes via DAVID, while ‘‘GO biological process complete’’ was the
annotation dataset employed by PANTHER, the latter of which had the Overrepresentation Test set as the analysis type (released
on 07-11-2019) and the GO Ontology database set as the annotation version (released on 01-03-2020). Ingenuity Pathway Analysis
(IPA, QIAGEN Digital Insights, Redwood City, CA, USA) was used to determine significantly enriched pathways and upstream reg-
ulators for each major tissue/cell dataset. DEGs and expression values with adjusted p values at each time point were uploaded and
analyzed using ‘‘Core Analysis.’’ Comparison analysis was then performed across multiple time points for each tissue/cell type. The
Ingenuity Knowledge Base was used to rank canonical pathways based on all species datasets and score them using a z-score al-
gorithm that is calculated based upon uploaded dataset correlation with an activated state in that canonical pathway. P values were
computed by IPA using a Fischer’s exact test to determine the probability that the association between the genes in the uploaded
dataset and the genes in the canonical pathway are due to chance alone. Values obtained from IPA were graphed using Prism. Sta-
tistical information for IPA can further be found in related figures and figure legends. For Pathview Web analysis (https://pathview.
uncc.edu/, University of North Carolina, Charlotte, NC, USA), Entrez Gene IDs corresponding to DEGs and log2 FC were uploaded;
KEGG diagrams were overlaid with gene changes.58
Data visualization
Data were plotted using Microsoft Office Excel 2016, GraphPad Prism v7.0 and v8.3.1, Morpheus (https://software.broadinstitute.
org/morpheus/, Broad Institute, Cambridge, MA, USA), InteractiVenn (http://www.interactivenn.net/),59 FlowJo v10.0, CIBERSORT,
PANTHER v14.1, DAVID v6.8, IPA and Pathview Web. Related statistical information, where applicable, can be found in figures and
figure legends.Current Biology 31, 257–270.e1–e5, January 25, 2021 e5
